Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Actio Biosciences Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy
Thursday, July 31, 2025Actio Biosciences a clinicalstage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases today announced that the United...
AQNEURSA® (levacetylleucine) Recommended for EU Approval by the CHMP to Treat Niemann-Pick Disease Type C
Thursday, July 31, 2025IntraBio Inc a biopharmaceutical company focused on developing therapies for rare neurological diseases today announced that the European Medicines Agencys EMA Committee for Medicinal Products
Trust in Transition: Comms Leaders Address ESG, Digitalisation & Geopolitical Risk
Thursday, July 31, 2025Europes pharmaceutical sector stands at a pivotal juncture Geopolitical upheaval rising ESG demands and rapid digital innovation are reshaping how leaders protect reputation build trust and futureproof their organisations
Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer
Wednesday, July 30, 2025Atossa Therapeutics Inca clinicalstage biopharmaceutical company developing innovative medicines in oncology today announced positive written feedback from the US Food and Drug Administration FDA regarding the companys proposed dose optimization tria...
Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe
Wednesday, July 30, 2025Hoth Therapeutics Inc a clinicalstage biopharma innovator today announced its engagement with ICON Clinical Research Limited ICON to expand its Phase II Clinical Trial for cancer patients suffering from
FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
Tuesday, July 29, 2025Ascendis Pharma AStoday announced that the US Food Drug Administration FDA has approved SKYTROFA lonapegsomatropintcgd developed as TransCon hGH for the replacement of endogenous growth hormone in adults with growth hormone deficiency GHD a rare dis...
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
Tuesday, July 29, 2025Entera Bio Ltda leader in the development of oral peptides and protein replacement therapies announced today that in a written response to a Type A meeting request the US Food and Drug Administration FDA
Bayer provides regulatory update on elinzanetant in the U.S.
Monday, July 28, 2025Bayer today announced that the US Food and Drug Administration FDA has notified the company that it has extended the review period for the New Drug Application NDA for elinzanetant the first neurokinin and neurokinin receptor
Solvias Expands U.S. Capabilities as RTP Center Becomes cGMP-Ready
Friday, July 25, 2025Solvias a global provider of chemistry manufacturing and controls CMC analysis today announced that its recently opened Center of Excellence for biologics and novel modalities in Research Triangle Park RTP
INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
Friday, July 25, 2025Gate Bioscience a biotechnology company developing molecular gates a new class of small molecule drugs to eliminate diseasecausing proteins at their source today announced a collaboration and license agreement with Eli Lilly
